| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | -0.04 | 0.2 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | 0.2 | 0.3 |
| mRNA | OSU-03012 | GDSC1000 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | etoposide | CTRPv2 | pan-cancer | AAC | -0.036 | 0.3 |
| mRNA | QS11 | CTRPv2 | pan-cancer | AAC | 0.081 | 0.3 |
| mRNA | EHT 1864 | GDSC1000 | pan-cancer | AAC | 0.04 | 0.3 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.041 | 0.3 |
| mRNA | Sunitinib | CTRPv2 | pan-cancer | AAC | -0.041 | 0.3 |
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | 0.079 | 0.3 |